Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D

 
• By Joseph Haas
  
Pedestrians wearing a protective mask walks past Pfizer Inc. headquarters on July 22, 2020 in New York City.
Pfizer will evaluate Voyager's AAV capsids as delivery mechanisms for gene therapy (Jeenah Moon/Getty Images)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business